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 The severity of the influenza outbreak in the United States during the 2017-18 season 
surpassed that of the 2016-17 season, with a case load reminiscent of the H1N1 pandemic of 
2009-10.  This increase in severity occurred despite the fact that both seasons’ H3N2 vaccine 
strain, derived from a clade 3C.2a virus, was from the same clade as the most commonly 
circulating viruses.  Previous work conducted in the Pekosz laboratory determined that, between 
the 2016-17 and 2017-18 seasons, viruses of the 3C.2a1 clade reassorted with both 3C.2a2 and 
3C.3a viruses.  It was hypothesized that these reassortments might have contributed to the 
observed increase in virulence during the 2017-18 season.  The results of these studies showed 
that 3C.3a viruses from both the 2016-17 and 2017-18 seasons, including the reassortant 3C.3a 
viruses, replicated to higher titers at earlier times post-infection in both immortalized cells and 
primary cell cultures than 3C.2a1 viruses.  Additionally, 2017-18 3C.3a reassortant viruses 
produced larger plaques than either 2016-17 3C.2a1 or 3C.3a viruses.  Taken together, these 
results suggest that 3C.3a reassortant viruses obtained a fitness advantage over the 3C.2a1 
parental strain.  To determine which gene segments were associated with this increased fitness, 
3C.2a1 viruses with gene segments from the 2016-17 season and a single gene segment from the 
reassorted 3C.3a virus – either HA, M or NS – were clonally generated and examined for their 
replication phenotypes.  An initial MDCK-Siat growth curve conducted with rescued 
monoreassortant 3C.2a1 viruses containing either 3C.3a HA, M or NS from the 2017-18 
reassortant 3C.3a clade showed that the 3C.2a1 virus bearing the 3C.3a HA gene segment best 
recapitulated the phenotype of the 2017-18 3C.3a reassortant virus, suggesting that the HA gene 
segment is contributing substantially to the difference in the phenotype observed between the 
3C.3a and 3C.2a1 clades. 
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Chapter 1 – Introduction 
Influenza Structure and Life Cycle 
 Influenza viruses are members of the Orthomyxoviridae virus family (23).  Their viral 
particles are enveloped, and their single stranded, negative sense genomic RNA is segmented 
(23).  There are four major subtypes of Orthomyxoviridae: A, B, C and D (30).  Influenza A and 
B are generally responsible for seasonal epidemics of flu in winter in the northern hemisphere 
(30).  Newly emerging forms of influenza A that are differ substantially from previous strains can 
cause pandemics.  Influenza C typically results in mild respiratory infections and is not thought to 
be associated with large-scale epidemics, while influenza D has thus far only been known to 
infect cattle (30).  A typical influenza A virion has eight gene segments: HA, NA, PB1, PB2, PA, 
NP, NS, and M (13). These gene segments are contained within a viral capsid, composed of 
multiple different M proteins, which is contained within a viral envelope. 
 During infection, hemagglutinin (HA) on the virion surface binds to sialic acid on the 
epithelial cell exterior, triggering receptor mediated endocytosis and bringing the virus into the 
host cell within an endosome (23).  As the pH drops inside the endosome, two key events occur: 
first, HA undergoes a conformational change, exposing a fusion domain that inserts itself within 
the endosome’s membrane (23).  Additionally, the matrix 2 (M2) ion channel opens and allows 
protons to flow into and acidify the viral core.  This acidification causes matrix protein 1 (M1) to 
release viral ribonucleoprotein (vRNP), a complex of viral genomic RNA and nucleoprotein, NP, 
as well as polymerase protein subunits PA, PB1, and PB2, into the host cell cytoplasm (23). 
 Once in the cytoplasm, the vRNPs traffic to the nucleus thanks to the presence of nuclear 
localization sequences (NLSs) on each of its components (23).  These NLSs can bind to the 
nucleus’s import machinery.  Following nuclear import, replication and transcription occur.  Both 
these processes are accomplished with a viral RNA-dependent RNA polymerase (RdRp), 
imported as part of the vRNP complex –  PA, PB1, PB2 (23).  Replication proceeds when RdRp 
produces positive-sense RNA from genomic negative-sense RNA, which allows for the 
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production of new genomic negative-sense RNA (23).  Furthermore, the positive-sense RNA 
generated by RdRp can serve as viral messenger RNA (mRNA) to enable the production of new 
viral proteins, with some modifications.  Since viral transcription takes place inside the nucleus, 
viral mRNA requires 5’ phosphate caps in order to be exported and targeted to the ribosome (23).  
Viral proteins are incapable of creating these caps, but they are quite effective at stealing 5’ caps 
from host cell mRNAs (23).  PB2 binds to host mRNAs and cleaves 5’ caps, which prime RdRp 
to perform viral transcription through a mechanism known as cap-snatching.  Production of poly-
A tails occurs due to steric blockage of RdRp as it repeatedly transcribes short, 3’ terminal poly-
U genomic RNA sequences in a “stuttering” process (23). 
 While this mechanism of transcription is successful at producing mRNA for six of the 
gene segments, splicing is needed for segments M (which encodes for both M1 and M2) and NS 
(which codes for NS1 and NEP) (23).  Host splicing machinery is inhibited from acting upon 
cellular mRNAs as NS1 binds to splicing components and is instead recruited to viral gene 
segments, where it splices the viral M and NS segments to allow for all encoded mRNAs to be 
produced.  These spliced RNA products then undergo cap-snatching and polyadenylation through 
the mechanisms described above (23).   
 Once viral mRNAs possess the necessary 5’ phosphate cap and 3’ poly-A tail, they will 
then be exported from the nucleus and translated at the ribosome (23).  As M1 is produced, it is 
brought into the nucleus to help mask an NLS present on vRNPs (23).  NEP then binds to the 
NLS present on the M1 N-terminal domain, which allows for the complex to be exported from 
the nucleus (23).  As HA, neuraminidase (NA), and M2 are translated they begin assembling into 
new viral particles at the apical side of infected epithelial cells.  M1 bound to vRNPs will be 
packaged into the nascent virions.  Ideally (for the virus) the forming virions will seal off once 
vRNPs for all eight gene segments are successfully incorporated (23).  After packaging is 
complete the virus will then begin to bud from the plasma membrane of infected cells.  Since the 
membrane enveloping the virus might contain sialic acid that could bind to neighboring virions’ 
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HA, NA must cleave these residues to ensure successful release of the virus from the cell surface.  
After release from the apical surface of the infected cells, the new viral particles can then go on to 
infect neighboring cells (23).   
 
Influenza A Host Tropisms and Evolution 
Influenza A infection proceeds differently in reservoir and spillover hosts (31).  Reservoir 
aquatic birds may experience asymptomatic or mild infections by influenza characterized by 
diarrhea.  Mammalian hosts, including (but not limited to) humans, dogs and pigs typically suffer 
more severe symptoms that include respiratory distress, fevers and body aches (31).  The 
transmission of newly evolved influenza A viruses (IAVs) from their natural aquatic fowl 
reservoirs to humans is thought to require (or at least benefit from) intermediate hosts, especially 
pigs (14).  To understand why, a brief discussion of the structure of sialic acid, the cellular 
receptor recognized by IAV’s HA protein, will be necessary. 
Sialic acid present on the surface of airway epithelial cells is attached to penultimate 
galactose residues found on N-linked carbohydrates attached to proteins (11).  This linkage 
occurs between the second carbon in the sialic acid ring and either the third or sixth carbon in the 
galactose ring-see figure 1.3 for a diagram of these linkages (11).  Which carbon-linkage sialic 
acid possesses to the galactose causes it to be named, respectively, (2,3) or (2,6) sialic acid (11).  
These different bonds create a selective pressure for any IAV attempting to infect the associated 
species, since HA must be able to bind the present sialic acid to initiate endocytosis.  Typically, 
human nasal epithelial cells carry much more (2,6) compared to (2,3) sialic acid on their surface 
(11).  Most IAVs emerging from their reservoir host of aquatic fowl are adapted to the (2,3) sialic 
acid present on the surface of their epithelial cells, while human viruses must recognize (2,6) 
sialic acid present on our epithelial cells (14).  Therefore, avian viruses have a difficult time 
infecting human nasal epithelial cells compared to human-adapted viruses.  However, pigs’ nasal 
epithelial cells express both (2,3) and (2,6) sialic acid, which enables them to be infected by 
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influenza viruses originating from water fowl and human hosts (14).  This can present (2,3) 
adapted IAVs originating from birds the opportunity to mutate and recognize (2,6) sialic acid, 
thereby becoming infectious to humans. 
 Such adaptations can occur in one of two ways – mutation or reassortment – both of 
which occur due to the segmented nature of influenza’s RNA genome (32).  Mutation, or genetic 
drift, results from erroneous additions of nucleotides to newly forming genomic viral RNA 
strands during replication (32).  The error rate of influenza A RdRp, which has no proofreading 
function, is roughly equivalent to 1 per genome produced (10).  Since many thousands of 
genomes can originate from a single infected cell, this means that many mutations can 
accumulate in a single individual infected with IAV that can then be transmitted to the next host, 
where new mutations can compound already existing ones before being passed to the next host, 
and so on (10).  These drift mutations can give rise to strains of influenza circulating between 
different influenza outbreak seasons. 
The second way mutations can occur within influenza genomes is called reassortment, or 
antigenic shift (32).   During viral particle packaging, vRNPs with each of the eight IAV gene 
segments are loaded into nascent virions.  While there is some evidence that this occurs in a 
specific manner so that multiple copies of the same gene segment are not usually loaded into the 
same virion, there is no requirement that all of the vRNP gene segments in any given virion must 
originate from the same parental virus (23).  If an epithelial cell were infected with two or more 
strains of influenza simultaneously, then some viral particles would by chance possess gene 
segments from each of the parental strains.  These new combinations of gene segments can 
produce viruses against which hosts have no immunity.  Depending on the virulence of the new 
strains and their transmissibility, this can give rise to pandemics (32).  Returning to the discussion 
of sialic acid momentarily, gene segment reassortment between avian and human influenza gene 
segments could occur within pigs thanks to their possession of both (2,3) and (2,6) sialic acid 
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(14).  Reassortment is the mechanism that is believed to have given rise to the 2009 influenza 
pandemic strain (18). 
 
Vaccinating Against IAV 
Reassortment events and drift mutations are critical to influenza’s ability to evade 
antibodies against previous years’ strains.  Typically, human anti-influenza antibodies form 
against HA (28).  Binding of antibodies to HA protects cells from infection by preventing the 
virus from binding to sialic acid.  Antibodies can also form against NA, which blocks newly 
budding viral particles from successfully exiting host cells by preventing the cleavage of sialic 
acid from HA (28).   
Vaccines against influenza virus begin production months before the flu season begins.  
How these vaccines are made is determined by what flu viruses were prominent during the 
previous year’s flu season, which provides information about what circulating strains might be 
most likely to emerge as dominant in the future (12).  Special attention is paid to the HA and NA 
proteins of these likely-dominant viruses since the immune system typically produces antibodies 
against them.  Production of vaccines begins by generating viruses with the desired combination 
of HA and NA genes (7).  Critically, these viruses must be capable of infecting embryonated 
hen’s eggs, the current standard for growing large quantities of vaccine stock.  Once eggs are 
injected, and viruses replicate to immunogenic titers, the viruses are harvested from the eggs (7).  
There are, however, some issues with this method of developing vaccines; one of the possible 
consequences is vaccine mismatch. 
Vaccine mismatch can result from the vaccine manufacturing process itself.  Since hens’ 
eggs are used to culture vaccine strains of influenza, the virus is under selective pressures unique 
to replicating within the eggs (28).  These pressures would be absent within the human host, 
which could result in mutants with traits favorable to the egg host outcompeting the desired 
vaccine strain originally injected into the egg.  Then, when the virus is harvested from the eggs, 
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its protein epitopes might not be identical to the ones found in the naturally circulating strains 
(28).  Any antibodies made against the egg adapted vaccine strains might be less effective against 
the seasonal strains as a result (28).    
Another problem with developing vaccines in hens’ eggs is time.  Egg procurement, viral 
growth, and the harvesting, preparation and testing of vaccines all need time to complete (7).  
This process takes months, and the vaccine produced cannot readily be adapted if the dominant 
circulating seasonal influenza strains mutate during the time it takes to produce the vaccine.  Any 
mutations, whether they be drift mutations in the gene segments themselves that result in protein 
epitope changes or reassortment events that produce new influenza A viruses altogether, might 
alter the immunogenic epitopes of the circulating seasonal flu such that the antibodies elicited by 
immunization have little to no protective effect (7).   
 
Seasonal Influenza Outbreaks in the United States, 2016-17 and 2017-18  
 The 2016-17 influenza outbreak in the U.S. was dominated by influenza A viruses of the 
H3N2 subtype (8).  Compared to past outbreaks, the 2016-17 season was relatively mild, with 
numbers of cases consistent with recent seasons.  During the 2016-17 season, the dominant 
circulating strains of IAV belonged to the H3N2 clade 3C.2a1 (3).  The vaccine strain deployed in 
the 2016-17 season included influenza A H3N2 3C.2a Hong Kong, which seemed relatively 
effective at controlling the number of cases of influenza. 
 For the 2017-18 influenza season, the Hong Kong derived vaccine strain was again 
employed as the H3N2 component (2).  Influenza A subtype H3 accounted for the majority of 
cases in the 2017-18 flu season just as it did in the 2016-17 season (3).  This suggests that the 
IAV H3 Hong Kong vaccine was still poorly protective against H3N2 strains circulating in the 
United States in the 2017-18 season.  Figure 1.4 shows that there were more cases of influenza-
like illness reported to outpatient clinics in the 2017-18 season as compared to 2016-17 (3).  
Correspondingly, the 2017-18 season found more patients hospitalized with influenza-like illness 
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than the 2016-17 season (8).  The IAV H3N2 Hong Kong derived vaccine was used in both 
seasons, yet cases of and hospitalizations from influenza-like illness were both significantly 
higher in the 2017-18 season (8).  If the vaccine were equally as ineffective in both seasons, we 
would not expect to see such a large difference in the number of cases or hospitalizations.  
Something must have changed about influenza between the 2016-17 and 2017-18 seasons that 
can account for the observed increase in transmissibility and virulence. 
 
A Novel Reassortment Event Between Two Influenza A H3N2 Clades 
 Earlier, two ways in which IAVs can mutate – genetic drift and reassortment – were 
discussed. (32).  Typically, drastic increases in transmissibility and virulence like those observed 
between the 2016-17 and 2017-18 seasons occur when there is a reassortment event that 
significantly alters the circulating viruses, as was believed to have occurred during the 2009 
pandemic influenza season (18).  Reassortment is uncommon for several reasons. First, a host cell 
must be infected with multiple different strains of IAV simultaneously.  Second, gene segments 
from different IAV parental viruses must randomly be incorporated into a nascent virion.  Third, 
any virions produced by the reassorted gene segments must successfully be able to exit their host 
cell and infect new cells.  Should these conditions be met, reassortant IAVs could be quite 
phenotypically distinct from any parental viruses from which they were derived, resulting in the 
ability to infect new host organisms, evade extant antibodies within their host populations, 
replicate more rapidly, spread more easily, cause greater morbidity and potentially mortality in 






Between the 2016-17 and 2017-18 flu seasons in the United States there was a 
reassortment event between viruses of different H3N2 clades.  The schematic for these 
reassortments is shown in figure 1.1 (manuscript in progress).   
During the 2016-17 influenza season, three viral clades of H3N2 circulated with no 
evidence of any reassortment between their genomes: 3C.2a1, 3C.2a2 and 3C.3a. (4).  In the 
2017-18 flu season, 3C.2a1 gene segments identified by sequencing were found in circulating 
3C.2a2 and 3C.3a viruses, which suggested that reassortment had occurred between viruses of 
these clades.  Specifically, 3C.3a viruses isolated within the Johns Hopkins Centers for 
Excellence in Influenza Research and Surveillance (JH CEIRS) during the 2017-18 season 
contained five 3C.2a1 gene segments (PB1, PB2, PA, NP and NA) and three 3C.3a gene 
segments (HA, M, and NS), referred to as a 5:3 reassortment (manuscript in progress).  3C.2a2 
viruses also underwent a reassortment event, combining six 3C.2a1 gene segments (PB2, PA, NP, 
NA, M, and NS) with two 3C.3a gene segments (PB1 and HA), or a 6:2 reassortment (manuscript 
in progress).  The 5:3 reassortant 3C.3a viruses isolated in the 2017-18 flu season were the focus 














Hypothesis and Research Aims 
 Based on the enhanced severity and number of cases associated with the 2017-18 U.S. 
influenza season, it was hypothesized that the 3:5 reassortment event between the 3C.3a and 
3C.2a1 clades conferred the reassortant viruses with increased viral fitness compared to the 
circulating 3C.2a1 viruses from the 2016-17 outbreak, which could have been responsible for 
some of the increased transmissibility and virulence noted in the 2017-18 outbreak.  To test this 
hypothesis, work centered on these specific research aims: 
1. Phenotypic characterization of the 3C.2a1 and 3C.3a viruses circulating in the 2016-17 
season and the 3C.3a viruses collected in the 2017-18 season.  This aim will be the topic 
of chapter two. 
2. Generating and phenotypically characterizing recombinant viruses through cloning that 
represented different combinations of reassorted gene segments from the 3C.2a1 and 
3C.3a viruses to determine which segments contributed significantly to the phenotype of 










































During the U.S. 2016-17 seasonal outbreak of influenza, 
circulating strains of H3N2 influenza could be classified 3C.2a1, 
3C.2a2 and 3C.3a clades.  Between the 2016-17 and 2017-18 
seasons, two reassortment events occurred: the 3C.2a2 HA and 
PB1 gene segments reassorted into a 3C.2a1 background.  
Separately, 3C.3a HA, M, and NS reassorted into a 3C.2a1 
background.   
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Chapter 2 – Phenotypic Characterization of Clinically Isolated Viruses 
Experimental Rationale 
 These experiments aimed at elucidating two phenotypic characteristics of influenza A 
viruses – replication kinetics following infection and morphological differences in viral plaques 
in monolayer cultures.   
Replication rate is a useful proxy for viral fitness since it shows how rapidly different 
viral strains are reproducing in culture following infection with an identical initial concentration 
of virus.  Any differences in viral titers in supernatants collected from cells infected with different 
viruses, assuming that the initial doses were identical, can be said to be due to characteristics 
intrinsic to the viruses themselves.  Thus, if one strain or clade replicates more rapidly 
consistently than another, this is suggestive that the more rapidly replicating virus might possess 
an advantageous phenotype – which, in turn, could help explain the seasonal differences observed 
with the increase in virulence of the 2017-18 season compared to 2016-17.  In this chapter, 
growth curves on both primary human nasal epithelial cells (hNECs) and MDCK-Siat cells, 
followed by TCID50 on MDCK-Siats, were used to determine which viruses experienced more 
rapid replication kinetics. 
Plaque morphology is another proxy for viral fitness.  Plaques, or areas on culture plates 
with predominantly dead cells, form as a single virus infects a single MDCK cell, replicates 
within it, and infects nearby cells as progeny viruses bud from the originally infected cell.  An 
agar overlay ensures that viruses cannot freely diffuse through liquid media following budding 
and must infect adjacent cells.  Viruses that replicate and bud from cells more rapidly will infect 
adjacent cells at a higher rate than slower replicating strains, producing larger plaques.  
Therefore, plaque size is a proxy for how well viruses spread through environments where they 
cannot float freely through permissive aqueous media.  Since human nasal passages are coated in 
thick mucus that can block viral movement from one cell to the next, the plaque assay can 
provide a better understanding of how viruses behave in that kind of restricted environment. 
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Materials and Methods 
Common Cell Lines 
Experiments with viruses were conducted across four different cell types: MDCKs, 
MDCK-Siats, hNECs and 293T cells.  MDCK, short for Madin-Darby Canine Kidney cells, are 
immortalized canine kidney epithelial cells useful for their relative ease in culturing and 
susceptibility to influenza infection due to the presence of both (2,3) and (2,6) linked sialic acid 
(15).  MDCK-Siat cells are MDCK cells that express two-fold higher levels of (2,6) sialic acid 
compared to MDCK cells (15).  This results from a successfully maintained transfection of 
human alpha-2,6-sialyltransferase cDNA into MDCK cells (15).  Because the (2,6) linkage 
mirrors what is present in human nasal epithelial cells (hNECs) MDCK-Siat cells should be a 
good immortalized cell model for infection.  When possible, it was preferable to work with 
MDCK-Siat cells as compared to hNECs, since hNECs required greater maintenance and had to 
be acquired directly from human subjects.   
Experimental protocols for MDCK and MDCK-Siat cells were generally interchangeable.  
For abbreviation purposes, if cells of either type are referred to nonspecifically in a protocol, the 
shorthand “MDCK/Siat” will be used.   
 
Common Reagents 
 The following is a list of common reagents used across experiments in chapters 2 and 3 
for ease of reference. 
• Phosphate-Buffered Saline (PBS): Saline solution that includes dissolved phosphate, 
generally employed as a means to wash cells during passaging. 
• Phosphate-Buffered Saline with .1% by volume calcium and magnesium (PBS+): PBS 
supplemented with calcium and magnesium ions that help fix cells to wells in plates. 
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• Dulbecco’s Modified Eagle Media (DMEM): DMEM contains glucose, vitamins and 
amino acids essential for cellular growth.  It includes sodium bicarbonate as a pH 
indicator. (Yao, 2017) 
• Complete DMEM: DMEM that includes 10% by volume fetal bovine serum (FBS) and 
1% by volume each of the antibiotics glutamax (G) and penicillin/streptomycin (P/S). 
• Infectious Media (IM): DMEM that includes 1% by volume each of the antibiotics 
glutamax (G) and penicillin/streptomycin (P/S), and immediately prior to infection will 
typically be fortified with 1% by volume of 30% bovine serum albumin (BSA) and .1% 
or .2% by volume N-acetylated-Trypsin (NAT). 
• Trypsin: A lab stock of the enzyme trypsin, which is diluted 1:5 with PBS when needed 
to resuspend cells in fresh media during culture passage. 
• Paraformaldehyde: A lab stock of paraformaldehyde, which was diluted to 4% in PBS to 
fix cells following an infection for analysis. 
• Naphthol Blue Black: A dye mixed with glacial acetic acid, PBS, sodium-acetate to stain 
fixed cells following fixation with paraformaldehyde. 
 
Virus Strains Studied   
 Initial growth curve experiments were conducted with one virus from the 3C.2a1 clade 
isolated during the 2016-17 season (R0145), one virus from the 3C.3a clade also acquired in the 
2016-17 season (0244), and one reassortant 3C.3a virus from the 2017-18 season (R0230).  In 
order to better understand the phenotypic changes between the reassortant 3C.3a circulating in the 
2017-18 season compared with parental 3C.3a and 3C.2a1 strains isolated in 2016-17, one 
additional virus from each clade was selected for further study, bringing the number of viruses 




Maintaining MDCK/Siat Cells 
 The basic technique of maintaining MDCK/Siat that follows is similar to the methods 
employed by Dr. Abdoli and his collaborators (15).  MDCK/Siat cells were split once every three 
to four days.  Splitting begins by washing MDCK/Siat cells with PBS, followed by suctioning of 
suspended cells.  5 mL of trypsin, diluted by a factor of 1:5 in PBS, was then pipetted onto the 
surface of the cell monolayer and incubated at 37 C for 20 minutes.  Following trypsinization, 5 
mL of complete DMEM would be added and pipetted up and down repeatedly to completely 
remove cells from the surface of the flask.  1 mL of cells, trypsin and DMEM would be left in the 
flask, and approximately 20 mL of DMEM would be added to allow the MDCK/Siat cells to 
repopulate.  The remaining 9 mL of cells could be used to prepare for future experiments or 
discarded if not needed. 
 
MDCK/Siat Low MOI Growth Curves  
Growth curves began by seeding MDCK/Siat cells onto 24-well plates at concentrations 
of 5x105 cells/well and incubating the plates at 37 C for sixteen hours.  Viruses would be diluted 
to an MOI of 0.001 through serial dilution on 96 well plates.  Following dilution, the 24-well 
plates bearing MDCK/Siat cells would be washed with PBS+ to ensure cell adhesion to the well.  
100 µL of each diluted virus would be pipetted into the appropriate wells, with each virus being 
grown in triplicate to generate three technical replicates.  A mock infection, consisting of 
infectious media prepared for the experiment that lacked virus, was also carried out in triplicate.  
The remaining inoculum would be saved at -80 C for verification that input concentrations of 
each virus were similar.      
Following infection, the 24 well plates would be rocked on an automatic plate rocker for 
one hour at room temperature to allow an even distribution of virus across the surface of the 
MDCK/Siat monolayer.  The viral media would then be aspirated and 500 µL of fresh infectious 
media would be applied to each well.  The 24 well plates would then incubate at 32 C for the 
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remainder of the experiment.  Supernatants would be collected at 1, 12, 24, 36, 48 and 72 hours 
after this initial change in media.  Each time, fresh infectious media would be supplied to the cells 
to capture newly budding viral particles. 
After a growth curve was completed, the replication phenotype of the viruses at the 
different timepoint samples collected was characterized through a median tissue culture 
infectious-dose (TCID50) assay.   
 
TCID50 Assay  
 First, MDCK/Siat cells would be seeded into 96 well plates at a concentration of 1x105 
cells/well and incubate at 37 C for three days.  These seeded plates then were washed twice with 
100 µL of PBS+ and 180 µL fresh infectious media applied.  Until needed for infection plates 
were kept at 32 C.  Supernatant samples from the growth curves would then be serially diluted 
from their initial concentrations by factors of ten, from 1x10-1  to 1x10-8 in round-bottom 96 well 
plates.  20 µL of each diluted supernatant sample would then be pipetted to the appropriate wells 
of the MDCK/Siat seeded 96 well plates and incubated at 32 C for six days.  At the end of the 
incubation period, 75 µL of 4% paraformaldehyde would be added for three or more hours to 
each well to fix cells.  After decanting the media and paraformaldehyde, 100 µL of Naphthol 
Blue-Black stain would be added to each well for three or more hours.  Plates would then be 
washed with water and examined to quantify viral titers. 
 
Plaque Assay  
 
MDCK cells were used to examine differences in plaque morphology between the viruses 
in figure 2.1.  After trypsinization during splitting, 2.5 mL of MDCK cells would be seeded in 6 
well plates at a concentration of 5x105 cells/well.  To ensure uniform distribution of cells, the 
plates were gently rocked by hand after seeding.  Plates were then incubated overnight at 37 C.  
Once confluent within their wells, the MDCK cells would be washed twice with PBS+.  After the 
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wash step, 1 mL DMEM with P/S and G would be added to each MDCK well and the 6 well 
plates would be stored at 32 C until needed.   
24 well plates were used to dilute viral working stocks in preparation for infection.  720 
µL infectious media was added to each well of the 24 well plate.  Into the first well, 80 µL of 
viral working stock would be added and mixed via pipetting, and 1:10 serial dilution would be 
carried out so that the final well would have a concentration 1x10-6 of the initial working stock.  
After removing the DMEM from the MDCK seeded plates, diluted virus would be added to the 
appropriate MDCK wells.  Once infection began, the plates were incubated at 32 C for one hour 
with gentle agitation every fifteen minutes to distribute the virus evenly throughout the wells. 
During the hour incubation 2x DMEM media (containing twice the concentration of 
reagents found in DMEM, twice as much antibiotic as used in infectious media, and 10 mL of 
HEPES) was made and 2% agarose solution was microwaved, then stored in a 67 C water bath.  
At the end of the incubation step, viral media was aspirated from the 6 well plates and 2x DMEM 
and 2% agarose were mixed in a 1:1 ratio to generate 1% agarose DMEM media.  3 mL of 1% 
agarose DMEM media was applied to each well, and the 6 well plates were incubated in 32 C for 
three days or until plaques became visible to the naked eye.  Once plaques could be seen, 1 mL of 
4% paraformaldehyde was added per well for four or more hours, after which the agar overlay 
was removed.  1 mL of Naphthol Blue-Black dye per well was added to the exposed cells for no 
more than 1.5 hours, after which the dye would be washed off and plaque size quantified. 
Quantification of Plaque Assays  
To quantify plaque size and morphology, images taken of each 6 well plate via light 
dissection microscopy were examined to identify the highest concentration where wells had not 
been completely cleared of cells by the viruses.  Then, using the ImageJ software’s hand-drawn 
region of interest selection tool, plaques and areas immediately surrounding plaques where partial 
clearance was observed were circled.  If two plaques were adjacent to each other, a best 
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approximation of the size and shape of the plaque would be made based off of estimated plaque 
radius.  Plaques that abutted the edge of the well were not selected for quantification. 
hNEC Cell Maintenance 
 Human nasal epithelial cells (hNECs) were obtained from a collaborating lab that 
harvested them directly from human volunteers.  Upon receipt of the cells, fresh ALI media 
would need to be provided to the basolateral component of the well once every other day.  This 
replacement of media provided fresh nutrients to the hNECs.  Prior to their usage in growth curve 
experiments, hNEC wells would be monitored for potential contamination.  Any contaminated 
wells would be discarded prior to the commencement of any growth curve experiments. 
 
hNEC Growth Curves 
 DMEM infectious media without any N-acetylated trypsin was prepared for hNEC 
growth curves.  Viral dilution to an MOI of 0.01 was achieved via serial dilution on 96 well 
plates.  Prior to infection, fresh ALI media was supplied to the basolateral surface of the hNEC 
wells and the apical surface was washed twice with the hNEC infectious media, leaving the cells 
covered in wash media for five minutes in 32 C prior to aspiration.  After washing, 50 µL of virus 
from the inoculum sample was then applied to the apical surface of the hNECs, and the plates 
were incubated for two hours at 32 C.   
 Following infection and initial incubation, viral media was aspirated.  At timepoints 1, 
12, 24, 36, 48, 72, and 96 hours following the end of the initial two hour incubation, 100 µL of 
infectious media would be applied to the apical surface of the hNEC wells and the plates would 
be incubated at 32 C for ten minutes.  The infectious media would then be collected and stored at 
-80 C until needed for TCID50 assay.  At 48 and 96 hours post infection, ALI media from the 






 While growth curves and plaque assays could determine replication kinetics of the 
viruses under study, they were not well suited to characterize how efficiently viruses infected 
cells.  To study that question, flow cytometry was conducted on hNECs infected (according to the 
protocol outlined in the above section) by the six viruses in duplicate wells for 16 hours incubated 
at 32 C.  At the end of 16 hours the hNECs were trypsinized and pelleted via centrifugation into 
individual 15 mL conical tubes, where they were fixed with 2% paraformaldehyde.  Following 
fixation the cells were then resuspended and transferred to FACS tubes and washed twice with 
PBS.  Permeabilization buffer (0.2% by volume Tween-20 dissolved in FACS buffer, 0.3% BSA 
in PBS) was then added and cells were incubated with the buffer for 15 minutes at room 
temperature.  Following a wash with FACS buffer, the cells were then incubated for 30 minutes at 
room temperature with blocking buffer added.  Once washed again with FACS buffer, half of the 
experimental tubes would be exposed to both beta-tubulin and human anti-serum isolated from 
patients in the 2016-17 outbreak containing polyclonal antibodies against 3C.2a1 viruses 
circulating at the time.  The other half of experimental tubes would only be inoculated with beta-
tubulin.  Both halves needed to be incubated for 20 minutes at room temperature, then washed 
with FACS buffer.  Goat serum containing anti-mouse IgG antibodies (goat anti-mouse IgG AF 
488) and goat serum with anti-human IgG (goat anti-human AF647) were then added to all 
experimental tubes and incubated for 20 minutes at room temperature.  Following another FACS 
wash, EpCAM-PE (an antibody against epithelial cell epitopes present on the surface of epithelial 
cells) was added to each experimental tube and incubated for twenty minutes.  Tubes were then 








Initial Low MOI Growth Curves 
The phenotypic effects that reassorting the 3C.3a 2016-17 gene segments HA, M and NS 
into a 3C.2a1 background had on virus replication were first characterized by low multiplicity of 
infection (MOI=0.001) growth curves.  It was unknown which cell type would better permit the 
clinically isolated 3C.2a1 and 3C.3a viruses from the 2016-17 and 2017-18 U.S. flu seasons to 
replicate.  To determine this, initial growth curves were done in both MDCK and MDCK-Siat 
cells.  At first, TCID50 assays were only carried out on the inoculum and 72 hours post infection 
(HPI) timepoint; if there was no virus present at 72 HPI despite being detected in the inoculum, 
there would be no need to measure titers of time points before 72 HPI.  Figure 2.2 shows the 
TCID50 results for the first MDCK growth curve conducted on the inoculum and 72 HPI samples. 
At an MOI of 0.001, none of the viruses applied to MDCK cells showed infectious 
particle production after 72 hours (Figure 2.2).  However, TCID50 assays showed that the same 
viruses at the same MOI infecting MDCK-Siat cells could replicate at 72 HPI (figure 2.3).  These 
experiments demonstrated that MDCK cells seemed refractory to infection with this panel of 
viruses, so MDCK-Siat cells were chosen for more extensive analysis of viral replication.  
Furthermore, the initial TCID50 data on MDCK-Siat cells seemed to suggest that 3C.3a viruses 
replicated better than 3C.2a1 viruses, and that the 3C.3a reassortant from 2017-18 replicated to 
higher titers faster than the 3C.3a parental virus from 2016-17.  
 
MDCK-Siat Growth Curves with more clinical isolates 
 The initial MDCK and Siat growth curves were only performed with one virus from each 
clade.  To more definitively characterize the phenotypic differences between the clades, more 
viruses and repeated experiments were needed.  Multiple clinical isolates of H3N2 influenza A 
viruses isolated from Baltimore patients during the 2016-17 and 2017-18 outbreaks, including 
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several viruses of both clades 3C.2a1 and 3C.3a, were available for study.  Two viruses from each 
clade (see figure 2.1) were selected for all future experiments. 
 Three separate low MOI=0.001 MDCK-Siat growth curve experiments were conducted 
with these six viruses, with each virus undergoing three technical replicates in each experiment 
(figure 2.4).  The results of each growth curve’s TCID50 are shown in panels A, B and C.  Panel D 
collapsed data across all three growth curves.  Each experiment showed the similar trends to those 
present in the initial MDCK-Siat growth curve; 3C.3a parental and reassortant viruses replicated 
to higher viral titers with faster kinetics than 3C.2a1 viruses.  However, the 3C.3a reassortant 
viruses did not replicate to higher titers or with faster kinetics than 3C.3a parental viruses. 
 
hNEC Growth Curves 
 MDCK-Siats are immortalized kidney epithelial cells, and therefore, not a typical cell 
line that influenza would encounter in the course of a natural infection.  To ensure the phenotypes 
observed in the MDCK-Siat cells were not anomalous, it was important to perform growth curve 
experiments in hNECs isolated from healthy individuals.  Figure 2.8 summarizes the hNEC 
growth curve experiments conducted thus far to characterize the panel of clinically isolated 
viruses selected for this research.  The phenotypes observed in the hNECs were consistent with 
the work conducted in MDCK-Siat cells, indicating that these viruses behaved similarly and, 
therefore, that the observed phenotype in the MDCK-Siat cells was conserved in a primary 
epithelial cell culture system. 
 
Plaque Morphology Characterization 
 To characterize the differences in plaque morphology between the panel of viruses under 
study, MDCK cells, which are permissive for plaque formation with 2016-17 H3N2 viruses 
despite the fact that they do not support the production of infectious virus (see Figure 2.2), were 
used.  Three plaque assays were performed, with each virus having two technical replicates per 
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assay.  The results of the individual plaque assay replicates are displayed in figure 2.6, panels A, 
B and C.  Panel D collapses the data across all three experiments.  Panels E, F and G are 
representative images of the indicated viral clades. 
Figure 2.7 summarizes the data from the collapsed analysis of all three biological 
replicates.  2016-17 3C.3a parental viruses exhibited plaque size area 50% greater than 2016-17 
3C.2a1 parental viruses, while 2017-18 3C.3a reassortant viruses produced plaques 85.5% greater 
in size than 3C.2a1 parentals.  Within the 3C.3a clade, the reassortants produced plaques 23.7% 
larger than parentals. 
 
Flow Cytometry 
 Figure 2.8 summarizes the results of the initial flow cytometry experiment.  No 
statistically significant differences were detected between the viral clades with regard to the 
percentage of cells, epithelial cells, or ciliated epithelial cells infected.   
 
Discussion 
 MDCK cells are used throughout the Pekosz laboratory as a typical cell-line for growth 
curves, TCID50s, and plaque assays.  It was unusual that the IAVs isolated from the 2016-17 and 
2017-18 seasons seemed unable to effectively infect MDCK cells at low MOIs associated with 
growth curves.  Following the initial growth curves in both MDCK and MDCK-Siat cells, growth 
curves in immortalized cells were conducted exclusively on MDCK-Siat cells.   
The initial MDCK-Siat growth curve (Figure 2.3) suggested that there was a measurable 
phenotypic difference in replication rates of 2016-17 3C.2a1 compared to both 2016-17 parental 
and 2017-18 reassortant 3C.3a viruses, and even between the parental and reassortant 3C.3a 
viruses.  For training purposes, these initial growth curves were only conducted with one virus 
from each clade.  To garner more statistical power for future analysis, subsequent growth curves 
included two viruses each clade (Figure 2.1). 
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 As figure 2.4 demonstrates, the phenotypic differences between 2016-17 3C.2a1 viruses 
and 3C.3a viruses from both 2016-17 and 2017-18 were consistent throughout biological 
replicates.  In each experiment, the 3C.3a parental and reassortant viruses always grew more 
rapidly to higher titers than the 3C.2a1 viruses.  Unlike the initial MDCK-Siat growth curve, the 
2017-18 3C.3a reassortant viruses did not exhibit a clear replication advantage compared to the 
2016-17 parental 3C.3a viruses.  In each biological replicate and after collapsing across all three, 
there was no statistically significant difference at two or more time points between the 3C.3a 
reassortant and 3C.3a parental viruses (Figure 2.4).   
Analysis of the hNEC growth curve experiments returned similar results – there were 
never consistent differences between the 2016-17 and 2017-18 3C.3a viruses, while both the 
reassortant and parental 3C.3a viruses grew more rapidly than 3C.2a1 viruses (Figure 2.5).  Since 
hNECs represent a model closer to actual infection of a human than MDCK or MDCK-Siat cells, 
their results are considered a gold standard in the Pekosz laboratory.  Therefore, agreement 
between the  hNEC and MDCK-Siat results bolstered the significance of the MDCK-Siat findings 
and meant that, in future experiments, results in MDCK-Siat cells would likely represent what 
would be observed in hNECs – at least for these H3N2 strains. 
 Given the difficulty in growing these viruses on MDCK cells during the initial growth 
curve experiments, there was some concern regarding whether plaque assays would be successful 
since they must be conducted with MDCK cells.  However, as Figure 2.6 shows, plaque 
formation within MDCK cells was successful.  This is potentially because plaque assays measure 
the spread of viruses to neighboring cells (cell-to-cell spread) while growth curves measure the 
release of infectious virus particles.  MDCK cells maintain the ability to support cell-to-cell 
spread of 2016-17 H3N2 viruses and, therefore, can be used to study plaque formation.   
By eye, the plaques formed by 3C.2a1 parental viruses appeared smaller than those 
produced by either parental or reassortant 3C.3a viruses (Figure 2.6, panels E, F and G).  Results 
of plaque morphology quantification via ImageJ agreed with conclusions from MDCK-Siat and 
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hNEC growth curve data – 3C.3a viruses isolated from the 2016-17 and 2017-18 seasons 
generated larger plaques than 3C.2a1 viruses from the 2016-17 season.  Interestingly, the 3C.3a 
reassortants from 2017-18 produced plaques across all three experiments that were about 23% 
larger on average than the 2016-17 3C.3a parental viruses.  Given the inability of all three 
biological replicates of the plaque assay to capture this phenotypic difference between the 
reassortant and parental 3C.3a viruses, it would be difficult to draw any conclusions about fitness 
differences of the parental and reassortant 3C.3a viruses based on these MDCK plaque assays 
alone, especially since these data seemingly contradict the results from the gold standard hNEC 
growth curves (figure 2.5).  Nevertheless, since growth curves measure viral release into 
supernatant from infected cells, and plaque assays quantify how rapidly viruses can spread 
between adjacent cells, the results in figures 2.6 and 2.7 might be indicating that 3C.3a 
reassortant viruses from the 2017-18 season are capable of initiating cell-to-cell infections more 
rapidly than either the 3C.3a or 3C.2a1 parental strains.   
The initial flow cytometry experiment sought to determine whether the advantageous 
replication phenotype observed in the 3C.3a viruses as compared to the parental 3C.2a1 viruses 
might be due to the efficiency of infection of cells of each virus.  Each of the panel of viruses 
under study was used to infect hNECs in duplicate for 16 hours.  After collecting and processing 
cells, they were run on a flow cytometer and the results quantified via FlowJo.  Figure 2.8 
summarizes the efficiency of infection of each virus on total cells present in the samples (panel 
A), epithelial cells (panel B), and ciliated epithelial cells (panel C).  There were no statistically 
significant differences between the efficiency of infection between viruses of different clades 
across the three cell types probed.  Since this is only a single replicate, it is premature to conclude 
that 3C.3a viruses from the 2016-17 and 2017-18 U.S. flu seasons do not infect cells more or less 
efficiently than 3C.2a1 viruses from the 2016-17 outbreak – this phenotype must be confirmed 
with further replicates. 
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 In summary, 3C.3a viruses from both the 2016-17 and 2017-18 U.S. flu seasons 
replicated more rapidly to higher titers than 3C.2a1 viruses isolated in the 2016-17 outbreak, in 
both MDCK-Siat and hNEC growth curves.  Furthermore, 3C.3a viruses generated larger plaques 
than 3C.2a1 viruses, and there was a statistically significant difference between the plaque sizes 
of 3C.3a parental and reassortant viruses when collapsed across all three replicates.  Flow 
cytometry indicated no difference in efficiency of infection between the viruses under study, 













































































One virus from each clade (2016-17 3C.2a1, 2016-17 3C.3a, 
2017-18 3C.3a) was used to infect MDCKcells at a low MOI of 
0.001.  Each virus in this growth curve had three technical 
replicates.  The 72 hour post infection (HPI) timepoint was 
titered to determine if these viruses could infect MDCK cells.  























































One virus from each clade (2016-17 3C.2a1, 2016-17 3C.3a, 2017-18 3C.3a) was 
used to infect MDCK-Siat cells to determine if there were detectable phenotypic 
differences between clades.  Each virus in this growth curve had three technical 
replicates. 
Asterisks denote statistically significant differences (p<0.05) at two or more 
timepoints in a multiple-comparisons, two-way ANOVA between the clades 










Two viruses from the three clades under study (2016-17 3C.2a1, 2016-17 3C.3a and 2017-18 
3C.3a) were used to infect MDCK-Siat cells in low MOI (0.001) growth curves.  Each individual 
growth curve (panels A, B, and C) had three technical replicates for each virus.  Panel D shows 
the data from all three growth curves collapsed into a single graph. 
Asterisks denote statistically significant differences (p<0.05) at two or more timepoints in a 
multiple-comparisons, two-way ANOVA between the clades indicated by the brackets.  Error 







Two viruses from the three clades under study (2016-17 3C.2a1, 2016-17 3C.3a and 2017-
18 3C.3a) were used to infect hNECs in low MOI (0.1) growth curves.  Each individual 
growth curve (panels A and B) had four technical replicates for each virus.  Panel C shows 
the data from both growth curves collapsed into a single graph. 
Asterisks denote statistically significant differences (p<0.05) at two or more timepoints in a 
multiple-comparisons, two-way ANOVA between the clades indicated by the brackets.  























































Two viruses from each clade under study were used to infect MDCK cells, and 
plaque area was quantified for each virus.  Three biological replicates (panels A, 
B and C) were conducted with each virus having two technical replicates.  Panel 
D shows data from all three biological replicates collapsed into a single figure. 
Asterisks denote statistically significant differences (p<0.05) via one-way 
ANOVA between clades. 
Panels E, F and G are representative images of wells infected with a virus from 
each clade.  Panel E represents the 2016-17 3C.2a1 parental clade, panel F the 























































These data were collected across all three biological replicates of the plaque assays.  Column 1 
lists the viral clades, and column 2 shows their associated mean plaque area in mm
2
.   Column 
3 calculates the difference in plaque area means between each clade and the 2016-17 3C.2a1 
parental clade, and column 4 does the same using 2016-17 3C.3a as the reference.  Column 5 
takes the ratio between each clade’s mean plaque area and that of the 2016-17 3C.2a1 clade, 
while column 6 performs the same calculation using the 2016-17 3C.3a parental clade as the 
reference. 
Figure 2.8 
Panel A shows the percentage of cells exposed to human serum bound to goat-antihuman AF 
647 antibodies, representative of infected cells relative to all cells present in the sample. 
Panel B shows the percentage of cells exposed to human serum bound to Ep-CAM PE and 
goat-antihuman  AF-647 antibodies, representative of infected epithelial cells relative to all 
epithelial cells present in the sample. 
Panel C shows the percentage of cells exposed to human serum bound to Ep-CAM PE, goat-
antihuman AF-647 and beta-tubulin, representative of  nfected ciliated epithelial cells relative 
to all ciliated epithelial cells present in the sample. 
The asterisk indicates that one 3C.3a replicate during the infection of hNECs prior to flow did 
not properly infect the cells, and the data have been excluded. 
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Chapter 3 – Determining Phenotypic Contributions of Reassorted Gene Segments 
 
Experimental Rationale 
 The results obtained from the experiments described in Chapter 2 showed that reassorting 
3C.3a gene segments HA, M and NS into an otherwise 3C.2a1 background conferred upon the 
progeny virus enhanced replication phenotypes relative to the parental 3C.2a1 viruses from 2016-
17.  Since the three gene segments from the 3C.3a background represented the largest difference 
between the 3C.3a reassortant and 3C.2a1 parental viruses, it seemed likely that one or more of 
these gene segments might be contributing to the enhanced replication phenotypes observed in 
both the TCID50 and plaque assays. 
 To determine which gene segments were responsible, the phenotypic effects of each gene 
segment reassorted individually into a 3C.2a1 background on viral fitness would need to be 
examined.  To begin, the gene segments for a 3C.2a1 parental virus would have to be cloned into 
a vector capable of producing infectious virus particles.  pHH21 was chosen given its routine use 
in the Pekosz lab for cloning individual gene segments from IAVs.  Each gene segment that had 
undergone reassortment (HA, M and NS) from a 3C.3a reassortant virus from the 2017-18 season 
into pHH21 would also need to be cloned into pHH21 to generate recombinant reassortant 
viruses.    
 Once all 3C.2a1 gene segments, along with 3C.3a HA, M and NS had been successfully 
cloned into pHH21, viruses would be rescued by transfecting 293T cells with these cloned 
plasmids and expression plasmids that code for influenza A polymerase proteins to assist in 
producing new virions.  For control purposes, a recombined virus that contained all of the 3C.2a1 
gene segments and another virus that contained all three 3C.3a reassortant gene segments in the 
3C.2a1 background would be needed as they should recapitulate the phenotype of the clinically 
isolated 3C.3a reassortant and 3C.2a1 parental viruses.  Each single reassortant 3C.3a gene 
segment (HA, M and NS) in a 3C.2a1 background would be needed to test the phenotypic impact 
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they confer individually, as measured through TCID50 of supernatants obtained from an MDCK-



























Materials and Methods 
Cloning into pHH21 
 The plasmid selected for generation of infectious clones of the 3C.2a1 clinical isolate 
R0145 from 2016-17 was pHH21, diagrammed in figure 3.1.  pHH21 contains sequences of DNA 
recognized by the restriction enzyme BsmBI which, upon enzymatic digestion, expose 
palindromic nucleotide sequences that can ligate with DNA digested by either BsmBI or another 
restriction enzyme, BsaI.  These enzymatic cut sites are flanked by promoter and terminator DNA 
sequences for RNA polymerase I, which produces RNA without any 5’ or 3’ modifications, 
similar to that seen with influenza A virus genomic RNAs.  The presence of an ampicillin 
resistance gene allows for transformation of bacterial cells and subsequent selection on 
ampicillin-impregnated LB agar plates of colonies derived from bacterial cells that had 
successfully been transformed with pHH21. 
 
Common Cell Lines 
 For the amplification of pHH21 bearing 3C.2a1 and 3C.3a gene segments, the 
Escherichia coli DH5α cell line was used due to the ease with which it can be transformed with 
plasmids from the environment.  Immortalized human kidney 293T cells were used to produce 
infectious influenza A virus via transfection.  MDCK and MDCK-Siat cells (discussed at length 
in Chapter 2’s materials and methods section) were applied as an overlay to 293T cells to amplify 
nascent recombinant viruses produced from cloned gene segments.  Characterization of the 
generated recombinant viruses involved plaque assays conducted on MDCK cells and growth 
curves with subsequent TCID50 assays conducted in MDCK-Siat cells, whose protocols have 






Cloning Influenza A Viral Gene Segments into pHH21 
 Two viruses were selected for cloning: 2016-17 Baltimore isolated influenza A H3N2 
3C.2a1 R0145 and 2017-18 Baltimore isolated influenza A H3N2 3C.3a R0230.  Figure 3.2 
summarizes the gene segments cloned from each of these viruses and several characteristics of 
each gene segment, including length in kilo-basepairs, annealing temperatures and extension 
times used in PCR, the presence of enzymatic digestion sites for restriction enzymes BsaI and 
BsmBI within the open reading frame of the gene segments, and the expected fragment size via 
gel electrophoresis when digested by SalI and XmaI restriction enzymes. 
 
Polymerase Chain Reaction 
 The first step in inserting viral gene segments into pHH21 was to perform polymerase 
chain reaction (PCR) using primers specific to each gene segment to amplify each gene segment 
individually.  Reaction tubes were prepared by mixing together appropriate volumes of nuclease 
free water with 5x High-Fidelity PCR buffer, 5 µM forward and reverse primers specific for each 
gene segment (see figure 3.2), cDNA from the chosen virus (either R0145 or R0230), Phusion 
DNA polymerase and 10 mM dNTP.  After vortexing and centrifuging reaction tubes, a thermal 
cycler with a PCR program containing the appropriate extension time and annealing temperature 
for the gene segments undergoing PCR (see figure 3.2) would be used to carry out the reaction.  
 
Gel Electrophoresis 
Once the gene segments had undergone PCR amplification, gel electrophoresis was 
performed to determine if the gene segment was of the correct expected base pair length by 
comparing to a ladder of known size (figure 3.3 shows the ladder used, while figure 3.2 shows the 
expected length of each gene segment).  A 1% agarose gel solution was prepared by microwaving 
1 gram of agarose in 100 mL of milli-Q purified water.  Prior to casting, 10 µL of ethidium 
bromide was added to bind to the DNA and fluoresce under exposure to UV light.  After casting, 
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the gel would be loaded into an electrophoresis case and covered in TAE buffer.  Then, 10 µL of 
5x loading dye would be added to the 50 µL PCR product, mixed thoroughly, and loaded into a 
well on the gel.  Typically, gels would be run for one hour at 150 V or until the dye bands had 
visibly migrated approximately three-fourths of the distance from the well to the distal end of the 
gel.  Exposing the gel to UV light and comparing the length of bands in the PCR products against 
the expected length of bands for each gene segment (figure 3.2) would reveal whether PCR had 
successfully cloned the gene segment.  If so, the PCR products could be purified from the gel to 
continue processing. 
 
Gel Extraction  
Extraction from the 1% agarose gel was accomplished with a QIAquick Gel Extraction 
Kit, and the protocol followed was identical to the one provided (19).  Extracted PCR products 
were eluted in 30 µL of nuclease free water and were ready to process through enzymatic 
digestion. 
 
Enzymatic Digestion of pHH21 and/or gel-purified PCR products 
In order to prepare the amplified gene segment for insertion into pHH21, enzymatic 
digestion of both the gene segments and pHH21 needed to be performed in order to generate 
exposed palindromic sequences that could be ligated.  Figure 3.2 shows which gene segments 
would cut within the open reading frame of each gene segment (if a gene segment contains a 
BsmBI cut site inside its open reading frame, that segment would have to be digested via BsaI, 
and vice versa).  pHH21 was always digested with BsmBI. 
The reaction mixture consisted of nuclease free water, 10x Buffer 3.1, the gel extracted 
PCR products or pHH21, and the appropriate restriction enzyme.  After mixing, vortexing and 
spinning down the reaction tubes, they would be incubated overnight at different temperatures 
depending on the enzyme contained within the reaction (55 C for BsmBI, 37 C for BsaI).  The 
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following morning, the enzyme would be inactivated via incubation at their appropriate 
temperatures (80 C for BsmBI, 65 for BsaI) for 20 minutes.   
When digesting pHH21, prior to inactivating enzymes, 0.5 µL of alkaline phosphatase 
would be added to the reaction mixture to prevent re-ligation of pHH21 to itself.  After incubating 
at 37 C for one hour, the reaction would then undergo an inactivation incubation at 80 C for 20 
minutes.  
 
Purification of digested pHH21 and PCR products 
After enzymatic digestion the digested DNA was purified away from the digestion 
reaction solution with a QIAquick PCR Purification Kit.  The protocol used was identical to the 
one provided (21).  Purified PCR products would be eluted in 30 µL, while pHH21 would be 
more highly concentrated at 20 µL.  The concentration of each sample would then be measured 
on a NanoDrop spectrophotometer and recorded for calculations in the next step – ligation. 
  
Ligation of pHH21 to purified gene segment digestions 
A molar ratio of 1-part pHH21 to 3-parts gene segment insert was desired for optimal 
ligation.  An online calculator was used to obtain the correct volumes needed of purified gene 
segment insert and pHH21 (17), and the appropriate volumes of pHH21 and gene insert were 
added to a clean thermal-cycler tube, along with nuclease free water, T4 DNA ligase, and 10x 
buffer specific for the ligase.  In a separate tube, a no-insert control would be prepared as a 
negative control to guard against contamination.  Once the reaction tubes had been mixed by 
pipetting and centrifuged, they would be incubated in a thermal cycler overnight at 16 C. 
 
Transformation of DH5α Cells with pHH21+insert Plasmid 
Following ligation, the gene-segment bearing pHH21 needed to be amplified.  DH5α E. 
coli cells were used to achieve this.  First, these bacterial cells would be removed from -80 C 
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storage and thawed on ice for 20 minutes, during which time a water bath would be prepared at 
42 C.  After thawing, 5 µL of the ligation reaction would be added to a tube containing 50 µL of 
bacterial cells and mixed by pipetting.  This mixture would be incubated on ice for 30 minutes, 
after which the bacterial cells would be heat shocked in the 42 C water bath for 30 seconds, then 
immediately cooled on ice for two minutes.  Sterile SOC or LB media would be mixed with the 
DH5α cells.  Ampicillin-impregnated agar plates, after being warmed to room temperature, would 
be covered with DH5α cells using sterile glass beads. Once the beads had been removed, the 
plates would be incubated overnight at 37 C.  
After transforming bacterial cells plates were checked for colony growth.  If colonies 
were present on the pHH21 with gene segment inserted and absent on the no insert control plates, 
then colonies would be selected for growth in liquid culture.   
 
Growing Liquid Cultures of DH5α cells & Miniprep 
Culture tubes would be filled with 5 mL of liquid LB with dissolved ampicillin in 
preparation for DH5α cell inoculation.  Using a sterile pipette tip, up to six colonies from each 
gene segment-bearing pHH21 plate would be selected and inoculated into the appropriate culture 
tubes, which would be incubated overnight in a shaking incubator at 37 C, 250 rpm.  The 
following morning, tubes would be visually evaluated for bacterial growth, indicated by 
cloudiness in the media, and checked for contamination by foreign microbes.  Assuming both 
DH5α cell growth and an absence of contamination, the liquid cultures could then be processed 
through a miniprep to isolate the amplified plasmid DNA.  Additionally, 720 µL of liquid culture 
would be removed from the culture tubes and added to 180 µL of 80% glycerol solution and 
stored at -80 C for future use. 
A QIAquick Plasmid Miniprep kit was used to purify plasmid DNA.  The protocol 
followed was identical to the one provided in the kit (20).  Purified plasmid DNA would be eluted 
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in 40 µL of nuclease free water.  The concentration of the sample would then be obtained via 
NanoDrop spectrophotometer and recorded. 
 
XmaI and SalI Digestion of pHH21 with ligated gene segments 
Assuming a good quality and concentration of the miniprep purified plasmid products, 
the next step would be to subject the ligated pHH21 and insert to digestion with the restriction 
enzymes XmaI and SalI-a crucial preliminary step that determines whether the gene segment of 
interest had been successfully inserted into pHH21. 
For this reaction, 500 ng of plasmid DNA was added to nuclease free water, 10x 
CutSmart buffer, and both XmaI and SalI restriction enzymes.  Additionally, two control 
reactions were prepared: in the first, an empty pHH21 plasmid with no inserted gene segments 
would be loaded into a reaction tube with all components described above to determine what a 
no-insert sample would look like for comparison.  The second control would be consist of a 
pHH21 sample with a ligated gene segment being placed into a reaction tube with no XmaI or 
SalI, to provide a no-enzyme comparison.  Once all experimental and control tubes had been 
prepared, they would be loaded into a thermal cycler to incubate at 37 C overnight. 
The following day, a 1% agarose gel would be prepared and run according to the protocol 
discussed previously.  At the conclusion of the run, the gel would be examined to determine the 
length of the bands for each pHH21 and gene segment being verified  If the band lengths present 
in gel electrophoresis match the expected band lengths in figure 3.2, then the sample will most 
likely contain the inserted gene segment corresponding to those band lengths.  To verify this, the 
sample must be submitted to the Johns Hopkins School of Medicine sequencing facilities for 
sequence confirmation.  The generated sequence can then be compared (using the Geneious 
sequencing software) to the known sequence for the corresponding gene segment.  If there are no 
non-synonymous mutations within the open reading frame, then the plasmid with the insert may 
be expanded via ZymoPURE II MaxiPrep protocol to produce large quantities for rescue.   
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ZymoPURE II Maxiprep Expansion 
 From the glycerol stock solutions, an overnight culture of 150 mL in LB liquid media 
with ampicillin would be prepared.  The following day, the ZymoPURE II Maxiprep kit would be 
used to isolate plasmid DNA from the bacterial culture.  The protocol followed was identical to 
the centrifugation variant supplied in the kit (29).  After eluting plasmid DNA in 400 µL of 
nuclease free water, the isolated plasmid should then be evaluated via NanoDrop 
spectrophotometer to determine concentration and purity. 
 Assuming no contamination, the products of MaxiPrep should then be submitted for 
sequencing to determine if any mutations occurred during the MaxiPrep process.  If not, then the 
plasmid can be stored in -80 C until needed for producing infectious clones.  Once all 3C.2a1 
gene segments and the 3C.3a HA, M and NS gene segments have been successfully amplified via 
MaxiPrep it becomes possible to produce infectious clones of virus from the plasmids. 
 
Generating Infectious Clones from Plasmids 
Since viruses in the Pekosz lab are routinely grown in MDCK and MDCK-Siat cells, the 
first rescue experiments performed were meant to determine which cell type would be most 
conducive to rescuing these cloned viruses following transfection of 293T cells.  These 
experiments sought to answer two questions: could the 3C.2a1 rR0145 plasmids produce 
infectious clones, and which cell type between MDCK and MDCK-Siat would allow for optimal 
viral rescue?  Figure 3.4 diagrams the process of these initial experiments, while figure 3.5 
summarizes the viruses sought from rescue. 
To successfully rescue viruses from the cloned plasmids, viral polymerase protein-
expressing plasmids from the H3N2 A/Udorn/1972 virus strain were used to supply the 
polymerase activity needed to generate mRNA from the transcribed genomic RNA produced 
from inserted viral gene segments.  A strain of IAV isolated from a Victoria outbreak and cloned 
into pHH21, maintained by the lab and known to successfully be rescued at high titers, was used 
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as a positive control.  Negative controls included mixtures of plasmids for 3C.2a1 rR0145 that 
included no HA or NA segments, Victoria virus without HA/NA, transfection reagent that 
contained no viral gene segments and OPTI-MEM that contained no transfection reagent.   
 
Initial Rescue Experiments of 3C.2a1 rR0145 
In a six-well plate, 500 µL of Poly-L-lysine must be added to each well and evenly 
distributed via rocking.  Wells were then washed twice with PBS+.  293T cells could then be 
seeded into the wells at a concentration of between 2 and 3x105 cells/well.  After seeding, plates 
were incubated at 37 C for 24 hours.  The following day, wells were checked by light microscopy 
to verify that 293T cells had attained between 40-60% confluence.  If so, then transfection 
reagent TransIT-LT1 would be warmed to room temperature and vortexed.  A master mix of 
consisting of OPTI-MEM and TransIT-LT1 could then be prepared.  Aliquots of the master mix 
in Eppendorf tubes would then be mixed with the appropriate plasmids to generate the desired 
virus to be rescued (see figure 3.5), though for these initial experiments only the 3C.2a1 gene 
segments were used.  After preparing the control reactions (Victoria all plasmids, Victoria lacking 
its HA and NA gene segments, 3C.2a1 lacking its HA and NA segments, no transfection reagent 
and cells only), media would be aspirated off of the 293T cells.  Each well would then be washed 
with PBS+, after which 2 mL of OPTI-MEM would be added per well.  The appropriate 
transfection reaction complex would then be added to each well, and the cells would be incubated 
at 32 C for 24 hours. 
The next day, MDCK and MDCK-Siat cells were split and, following trypsinization, 
diluted to a concentration of 5x105 cells per well.  After achieving this concentration, the cells 
would then be spun down in a centrifuge and resuspended in infectious media.  The OPTI-MEM 
media within the 293T cell wells would then be aspirated, and 2 mL of the MDCK or MDCK-Siat 
containing infectious media would be deposited into the 293T cell wells.  The plates would then 
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be incubated at 32 C, and every 24 hours 1 mL of the supernatant would be collected for future 
use and replaced with 1 mL of freshly made infectious media per well.   
During these rescue experiments, monitoring for cytopathic effects (CPE) helps gauge the 
success of each rescue, but subsequent verification of infectious virus presence is needed.  This 
can be done via plaque assay of the rescue supernatants from each time point where CPE were 
observed.  If CPE was not obvious in the wells, TCID50 can be performed to determine whether 
virus is present in the supernatants, which can determine which supernatants would likely 
produce the best plaques in a subsequent plaque assay. 
For the first rescue experiments, TCID50 was performed on both MDCK and MDCK-Siat 
cells using the same protocols from chapter 2 (Figure 3.13).  This was done to determine which 
cell type would be best for future titering experiments of rescued viral supernatants.  Consistent 
with results from chapter 2, MDCK-Siat cells were better both for overlay of 293T cells and 
subsequent titering and, therefore, were used in future experiments for these purposes. 
  
Generation of Seed Stocks 
Once titering experiments confirmed the presence of viruses in the supernatant, plaque 
assays on MDCK cells were used to generate clonally pure samples of virus (as each plaque 
should derive from a single virus propagating through proximal cells).  To remove a plaque for 
isolation of virus, a specially prepared filtered pipette with a broad opening in its tip would be 
used.  Typically, plaques were picked three days after infection and the resulting agar plugs 
incubated in infectious media for between an hour and overnight at 4 C. 
Following incubation, the infectious media bearing the agar plug would then be used to 
infect confluent MDCK-Siat cells in a six-well plate, with one well being used for each picked 
plaque.  After washing the MDCK-Siat cells with PBS+ twice, 250 µL of the agar-plug bearing 
infectious media would be added to the appropriate MDCK-Siat well.  The plates would then be 
incubated at 32 C for one hour, after which the viral media would be aspirated off of the wells 
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and replaced with 2 mL fresh infectious media.  Following this, the plates would be placed back 
into the 32 C incubator and be monitored, daily, for the development of CPE.  Once 
approximately 50% of the cells within a well showed signs of CPE, 500 µL aliquots could be 
collected and stored at -80 C until needed. 
 
Extracting viral RNA 
Verification of seed stock sequences was crucial to ensure that no mutations had been 
introduced.  Segments HA, M and NS were of particular interest since they were reassorted 
between viruses of the 3C.2a1 and 3C.3a clades and were therefore the focus of sequencing 
efforts.  To do this, first viral RNA had to be isolated from the seed stock samples.  This was 
done using the Qiagen RNeasy Mini Kit, and the protocol followed was identical to the one 
supplied in the kit (22).  After eluting the RNA into 50 µL of nuclease free water, the RNA was 
placed into -80 C until needed for RT-PCR. 
 
Characterizing Rescued Viruses 
 To determine which gene segments were responsible for the faster replication phenotype 
observed in the 3C.3a reassortant viruses from the 2017-18 season compared with the 3C.2a1 
viruses from the 2016-17 season, MDCK-Siat growth curves were performed.  After collecting 
viruses at each time point, they were titered and the data compiled for analysis.  The protocols for 














Cloning R0145 & R0230 Gene Segments into pHH21 
 Figure 3.6 shows a composite gel image of two separate XmaI and SalI digestion 
reactions.  The gel on the left shows bands consistent with the expected band lengths following 
digestion of the M, NP, NS, PB1, HA and PA gene segments that I had processed from cDNA 
generated from clinically isolated 2016-17 3C.2a1 R0145 (see figure 3.2).  The gel at the right 
shows XmaI and SalI digestions for the gene segments NA and PB2 from the same virus.  Each 
digested gene segment produced bands consistent with expected gene segment lengths from 
earlier Geneious analysis, suggesting that initial PCRs and ligation reactions had successfully 
integrated the gene segments into the cloning vector pHH21.  Further verification was later 
obtained from sequencing analysis of submitted samples, which confirmed that each gene 
segment had been cloned into pHH21 and could proceed with viral rescue of rR0145. 
 Some difficulties were encountered in cloning R0230 HA, M and NS into pHH21.  M 
and NS were processed simultaneously in the beginning, producing the XmaI and SalI digestion 
gel seen in figure 3.7.  While subsequent sequencing verification confirmed that NS had been 
successfully ligated into pHH21, the “M” segments visible in this image were contaminated 
during processing and were sequenced matched with NS.  From there, the M segment cloning 
process was restarted.  Furthermore, there were problems cloning HA into pHH21 – figure 3.8 
shows an unsuccessful XmaI and SalI digestion of clonally selected pHH21 bearing HA, which 
should have three bands.  After consulting members of the Pekosz laboratory for assistance in 
troubleshooting, they recommended adjusting annealing temperatures and extension times during 
PCR.   
To optimize the PCR conditions, gradient PCR was performed for both R0230 HA and 
M.  The initial gel (shown in figure 3.9) with both gradient PCR products shows the results – HA 
seemed to amplify best at 65 C, while M did not amplify as well at the tested temperatures.  To 
obtain an optimal annealing temperature for the M segment, another gradient PCR for M at new 
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temperatures that were slightly lower than the initial range was conducted.  This time, M 
amplified best around 65.4 C (figure 3.10).  After reprocessing the samples from PCR to XmaI 
and SalI digestion using the new optimized conditions, HA bands (figure 3.11) and M bands 
(figure 3.12) consistent with predicted lengths were obtained.  Subsequent sequencing 
verification confirmed the successful integration of each gene segment into pHH21 and the 
plasmids were stored for future use in viral rescue experiments. 
 
Initial Rescue of rR0145 
 R0145 was cloned first into pHH21 first.  In line with the pipeline outlined in figure 3.4, 
it was important to verify that these gene segments were capable of producing infectious virus 
following transfection and determine the best cell type for overlay with 293T cells and 
subsequent titering of rescued viruses.  TCID50 results for the transfection supernatants are shown 
in figure 3.13.  In keeping with results from chapter 2, at low viral titers rR0145 could not easily 
infect MDCK cells, so much so that using MDCK cells as an overlay to 293T cells produced no 
measurable quantities of virus, even when titered on MDCK-Siat cells.  Moving forward, MDCK-
Siat cells were used for all rR0145 overlays and TCID50s as those conditions gave maximum 
amounts of infectious virus from the rescue supernatants (Figure 3.13).  Figure 3.14 shows the 
results of the negative controls lacking HA and NA in both Vic and rR0145, with no infectious 
viruses detected.  The positive control virus, Vic, was successfully rescued from all overlay 
conditions and titered well on both MDCK and MDCK-Siat cells (figure 3.15), suggesting that 
the difficulties encountered in rescuing rR0145 from MDCK cells were due to the virus, not 
deficiencies in the cell line. 
 
Rescue of rR0145 with R0230 gene segments 
 After confirming the viability of the rR0145 gene segments to produce infectious virus, 
R0230 HA, M and NS had been cloned into pHH21 and required testing to determine whether 
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these gene segments, in combination with R0145’s background, could successfully be rescued.  
To that end, I five plasmid mixes were prepared for transfection (summarized in the legend of 
figure 3.16).  As a positive control, 293T cells were transfected with all eight gene segments of 
R0145 since that virus had been successfully rescued in a previous experiment (figure 3.13).  One 
transfection consisted of all three R0230 cloned segments (HA, M and NS) combined with all 
other gene segments of R0145 to generate a virus that should be phenotypically similar to R0230.  
The three other transfections included only a single gene segment from R0230 in an R0145 
background (monoreassortant viruses) to test which gene segment (or segments) recapitulated the 
R0230 phenotype.  The results of TCID50 of the viral supernatants in figure 3.16 show the 
successful rescue of rR0145 with all plasmids from the R0145 background, as well as rR0145 
with R0230 HA, M and NS individually.  The triple reassortant (rR0145 with R0230 HA, M and 
NS in the same virus) was not successfully rescued in this first experiment.  A plaque assay of the 
rescued viruses was performed and seed stocks made.   
 A second viral rescue experiment was performed to obtain the triple reassortant rR0145 
with R0230 HA, M and NS.  Subsequent TCID50 quantification verified that the triple had been 
rescued (figure 3.17).  This experiment involved three conditions seeking to rescue the triple 
reassortant virus: one where the concentrations of 3C.3a segment-bearing plasmid were the same 
as the previous experiment, one in which they were doubled, and one in which both the 3C.3a and 
Udorn plasmid concentrations were doubled.  Figure 3.17 shows that the original plasmid 
concentration condition was the only triple-reassortant condition to yield any infectious viruses.  
While it was unusual that the rescue of rR0145, all plasmids, failed to produce any detectable 
clearance of cells in the TCID50, a plaque assay was performed to isolate clonally pure virus and 






Generating Seed Stocks of rR0145 and rR0145 with R0230 Segments 
 The goal of this plaque assay was to generate clonally pure viral samples for future 
characterization.  Distinct plaques should result from a single virus propagating through adjacent 
cells, and therefore should be identical to the progenitor virus responsible for infecting the first 
cell at the center of the plaque (barring any mutations).  After picking distinct plaques via 
micropipette tip and transferring them to infectious media, these isolated plaques were used to 
infect freshly plated MDCK-Siat cells.  Once approximately fifty percent of MDCK-Siat cells 
exhibited CPE, 500 µL aliquots were collected and stored at -80 C.  The initial plaque assay saw 
rR0145 all plasmids and the single reassortant rR0145 with either R0230 HA, M or NS all 
produce clonally distinct plaques, which were picked and grown for the production of seed 
stocks.  The second plaque assay, conducted with rR0145 containing all three R0230 segments 
HA, M and NS, was also successful and plaque picking produced monoclonal isolates of the 
triple reassortant virus. 
 
TCID50 of Seed Stocks of rR0145 and rR0145 with R0230 Segments 
 The seed stocks were titered in order to prepare working stocks and an MDCK-Siat 
growth curve at an initial MOI of 0.001.  The results of this TCID50 analysis of the rescued viral 
seed stocks are presented in figure 3.18.  Using these viral titers, a growth curve on MDCK-Siat 
cells was conducted using a rescued 3C.2a1 virus with all 2016-17 parental 3C.2a1 gene 
segments (rR0145), 3C.2a1 viruses including either the 3C.3a HA, M or NS gene segment in 
place of the 3C.2a1 gene segment, and clinically isolated 2016-17 3C.2a1 (R0145) and 2017-18 
3C.3a (R0230) viruses.  The results of TCID50 analysis of this growth curve are shown in figure 
3.19.  Consistent with work from chapter 2, the reassortant 3C.3a virus, R0230, replicated to 
higher viral titers at earlier timepoints than the parental 3C.2a1 virus, R0145.  Among the rescued 
viruses, rR0145 with 3C.3a HA replicated at earlier timepoints to higher titers than all other 




Figures 3.6, 3.11 and 3.12 show that all 3C.2a1 gene segments, as well as 3C.3a HA, M 
and NS, were successfully cloned into a pHH21 cloning vector for the eventual generation of 
rescued recombinant viruses.  While troubleshooting was extensive for these plasmids, all 
segments were sequence verified and subjected to Maxiprep amplification for use in rescue. 
Viral rescue experiments to isolate the necessary combinations of R0145 and R0230 gene 
segments proved successful, though only if 293T cells were overlaid with MDCK-Siat cells 
(Figure 3.13).  This is consistent with findings from chapter 2 that repeatedly showed that MDCK 
cells could only successfully be infected by the 2016-17 3C.2a1, 3C.3a and 2017-18 3C.3a 
viruses at relatively high MOIs (greater than 0.001 typically used for low MOI growth curves).  
Fortunately, since the desired viruses could be recovered from MDCK-Siat overlaid rescue 
experiments, we were able to proceed with characterization of the effects of each individual gene 
segment reassortment from the 2017-18 3C.3a reassortant virus, R0230, into the 2016-17 3C.2a1 
parental virus R0145. 
Since clinically isolated viruses produced the same phenotype in both MDCK-Siats and 
hNECs (see chapter 2), the recombinant reassortant viruses from rescue seed stocks could be 
characterized on the lower-maintenance MDCK-Siat cell line.  Figure 3.19 shows that, among the 
rescued recombinant viruses, the 3C.2a1 virus bearing the 3C.3a HA gene segment grew to the 
highest viral titers at the earliest timepoints.  This suggests that the reassortment of 3C.3a HA into 
a 3C.2a1 background is enough to induce a significant increase in viral fitness.  Because this is 
only an initial experiment with a single replicate, further study would be needed to confirm that 
3C.3a HA consistently leads to an increase in fitness when reassorted into a 3C.2a1 background.  
Furthermore, because inclusion of 3C.3a HA alone in an otherwise 3C.2a1 background was not 
enough to completely recapitulate the reassortant phenotype, this strongly indicates that the NS 
























































Diagram of the plasmid vector used for cloning, pHH21.  Of note are the BsmBI cut sites (in 
navy), the ampicillin resistance gene (in yellow), and the pHH21 primer binding sites (in 












This table shows the viruses (column 1) and gene segments from each virus (column 2) selected 
for cloning into pHH21.  Length of each gene segment is given in kilobasepairs in column 3.  
Primer set used to amplify each gene segment is provided in column four.  The annealing 
temperature and extension time used in PCR are supplied in columns five and six respectively.  
Column seven whether each gene segment contains digestion sites for BsaI and/or BsmBI 
within their open reading frames.  Column eight shows the expected fragment sizes, in 
basepairs, generated when each gene segment ligated into pHH21 is digested by restriction 































1 kb ladder used during gel electrophoresis for 
comparing experimentally generated fragments 
of nucleic acid to bands of known length (34). 
Figure 3.4 
This diagram shows the experimental procedures conducted to generate and confirm the 
presences of rescued viruses and to determine which cell type was better for future 
experiments.  First, pHH21 plasmids ligated to gene segments would be incubated with 293T 
cells overnight.  Then, either MDCK (blue) or MDCK-Siat (red) cells would be added as an 
overlay to allow nascent viral particles to amplify.  After collecting supernatant samples from 
the 293T cells overlaid with either MDCK or MDCK-Siat cells, titering would be performed 




































This table shows the viruses sought from rescue.  Sample IDs identify which gene segments 
are meant to be contained within each virus, with red boxes indicating a gene segment arose 
from the 3C.2a1 virus isolated during the 2016-17 outbreak, Baltimore R0145, and purple 
boxes that the segment originated from the 3C.3a virus isolated in the 2017-18 flu season, 
Baltimore R0230. 
Figure 3.6 
This composite gel image shows gene segments from 2016-17 H3N2 3C.2a1 Baltimore 
R0145 digested by the XmaI and SalI restriction enzymes, with ladders and a no restriction 
enzyme control displayed at far left.  Each gene segment was compared to the expected 





















This gel shows the XmaI and SalI digestion of the M and NS segments of 2017-18 H3N2 
3C.3a Baltimore R0230.  Samples M1, M3, M4 and M5, along with samples NS4 and NS5 
were submitted for sequencing.  The M samples submitted for sequencing were found to be 
contaminated with NS segment DNA, while the NS4 and NS5 samples submitted were pure. 
Figure 3.8 
This gel shows 2017-18 H3N2 3C.3a Baltimore R0230’s HA segment after XmaI and SalI 

















This gel shows the results of an annealing temperature gradient PCR experiment on 2017-18 
H3N2 3C.3a Baltimore R0230’s M and HA segments to determine the ideal annealing 
temperature for each reaction.  For HA, 65 C was selected for future experiments.  None of the 
M segment bands matched the intensity of the HA bands, and so a second gradient PCR 
experiment was necessary to identify the ideal annealing temperature. 
Figure 3.10 
This gel shows the results of the second annealing temperature gradient PCR experiment 
conducted on 2017-18 H3N2 3C.3a Baltimore R0230’s M segment.  The intensity of the band 
generated at 65.9 C, coupled with a lack of degraded bands, made this the temperature used 
























This gel shows the HA segment of 2017-18 H3N2 3C.3a Baltimore R0230 after XmaI and 
SalI digestion following PCR with the new annealing temperature derived from annealing 
temperature gradient PCR in figure 3.9.  Each sample contained the expected band lengths 
from figure 3.2.  
Figure 3.12 
This gel shows the HA segment of 2017-18 H3N2 3C.3a Baltimore R0230 after XmaI and 
SalI digestion following PCR with the new annealing temperature derived from annealing 
temperature gradient PCR in figure 3.9.  Each sample contained the expected band lengths 
















This graph shows the TCID
50
 results following the initial rescue experiments conducted with 
both MDCK and MDCK-Siat overlays on 293T cells.  Results from titering on both MDCK 
cells and MDCK-Siat cells are shown.  The purple bars represent data from titering 
experiments conducted with MDCK overlay on 293T cells, and titered on MDCK cells.  Blue 
represents an MDCK-Siat overlay whose supernatants were then titered on MDCK cells.  Red 
shows data from supernatants collected from an MDCK overlay that were then titered on 
MDCK-Siat cells.  Green displays data taken from supernatants collected from an MDCK-Siat 
overlay that were subsequently titered on MDCK-Siat cells.  The only conditions that showed 
successful virus generation were the conditions where MDCK-Siat cells were used to overlay 
293T cells (green and blue), and the best titering data came from MDCK-Siat cells (green).  
For all future rescue experiments, 293T cells would be overlaid with MDCK-Siat cells and 
titering of supernatants would be conducted on MDCK-Siat cells. 
Figure 3.14 
Each bar in this graph represents a negative control reaction where both the positive control 
virus, Vic, and the desired virus rR0145 lacked HA and NA in the initial rescue experiments.  
As expected, no titers were detected, regardless of MDCK or MDCK-Siat cell overlay on 293T 

















This graph shows the titering results from the positive control virus in the initial viral rescue 
experiment.  Consistent with previous results in the Pekosz lab, the virus was successfully 
rescued from both MDCK and MDCK-Siat overlays on 293T cells and could be titered 
equally well on both MDCK and MDCK-Siat cells. 
Figure 3.16 
This graph shows titering conducted of rescued viruses containing all gene segments from 2016-
17 H3N2 3C.2a1 Baltimore R0145 (red) or with gene segments from 2017-18 H3N2 3C.3a 
Baltimore R0230 replacing a single 3C.2a1 gene segment (HA in yellow, NS in blue, and M in 
green).  The triple reassortant 3C.2a1, supposed to contain 3C.3a HA, M and NS, was not 

















These titering data show the successful rescue of a recombinant 2016-17 H3N2 3C.2a1 
Baltimore R0145 containing HA, M and NS from 2017-18 H3N2 3C.3a Baltimore R0230 
following a troubleshooting experiment. Boosting the concentration of 3C.3a HA, M and NS 
plasmids in the absence (blue) or presence of doubled udorn expression plasmid concentrations 
(green) resulted in no infectious virus being generated, though standard concentrations of the 
3C.3a HA, M and NS plasmids (purple) did produce infectious virus..    
Figure 3.18 
These are titers of seedstocks of the rescued 3C.2a1 virus, rR0145, and each of the 
monoreassortant viruses (rR0145 with either HA, M or NS from 3C.3a R0230) that were used 











This MDCK-Siat growth curve titering data shows each of the rescued viruses (3C.2a1 
rR0145 with all 3C.2a1 plasmids, the monoreassortant rR0145 rescues with either 3C.3a HA, 
M and NS) as well as two clinically isolated viruses, 2017-18 H3N2 3C.3a reassortant 
Baltimore R0230 and 2016-17 H3N2 3C.2a1  Baltimore R0145, grown simultaneously.  The 
purple graph, representing the clinically isolated reassortant 3C.3a, again replicated earlier to 
higher viral titers than the parental 3C.2a1 in crimson, consistent with results from chapter 2.   
Of the rescued viruses, rR0145 with R0230 HA (green) most closely recapitulated the 
phenotype of the reassortant 3C.3a virus, growing to higher titers at earlier timepoints than all 
viruses (including the parental 3C.2a1 virus) except the actual reassortant R0230 virus. 
Error bars here represent standard error of means. 
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Chapter 4 – Conclusions 
Reassortment’s Association with Enhanced Viral Fitness 
 Growth curve experiments conducted on MDCK-Siat (figures 2.3-2.7) and hNECs (2.8-
2.10) demonstrated that reassortant 3C.3a viruses isolated in the 2017-18 US influenza season 
replicated to higher viral titers at earlier time points than parental 3C.2a1 viruses isolated in the 
2016-17 season.  If enhanced viral replication in these cell lines, especially hNECs, can be used 
as a proxy for in vivo transmissibility and virulence, then these results are consistent with the 
greater number of outpatient visits in the 2017-18 season resulting from influenza-like illness 
than during the 2016-17 season (8).  Therefore, the initial hypothesis – that reassortment of gene 
segments from the 3C.3a clade into a 3C.2a1 background could lead to increased viral fitness, 
thereby explaining some of the difference in the severity noted between the 2016-17 and 2017-18 
flu seasons (3) – is consistent with results obtained from experimental analysis of viral growth 
rates when compared to the relative severity of the two flu seasons under study.  However, the 
reassortant 3C.3a virus had similar replication kinetics as the 3C.3a parental virus, so 
reassortment did not improve the fitness when compared to that parental virus.   
 When trying to determine the relative effect that the 3C.3a reassortment might have had 
on the severity of the 2017-18 flu season, it is important to consider the relative number of cases 
of influenza resulted from 3C.3a infections.  Had 3C.3a experienced a surge in case numbers 
during the 2017-18 season and become the dominant circulating viral clade of H3N2, that would 
offer very strong evidence that the 3C.3a reassortment event played a large role in the increased 
severity of the 2017-18 season over that of 2016-17. The situation was not so simple, as can be 
seen in figure 4.1 (9).  Among specimens collected from influenza-positive patients across the 
United States by public health laboratories and reported to the CDC, 3C.3a viruses accounted for 
only 1% of all H3N2 cases in the 2017-18 outbreak, while 3C.2a viruses (including 3C.2a2 but 
excluding 3C.2a1) were reported in 84% of influenza cases (5).  In Baltimore, specimens 
collected as part of the CEIRS network found 3C.3a viruses representing a larger portion of the 
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influenza cases reported (19%), though 3C.2a2 viruses still accounted for substantially more 
cases (41%).  Since 3C.2a2 was more abundant in the United States during the 2017-18 outbreak 
(8), both nationally and within the CEIRS samples collected in Baltimore, perhaps the 3C.2a2 
viruses were more responsible for the increase in virulence noted in that season.  To more fully 
grasp the effect of reassortment on H3N2 viral fitness, and the potential impacts thereof on inter-
seasonal differences in case-load and severity of influenza in the U.S., a discussion on 3C.2a2’s 
reassortment event is necessary. 
 While this research focused on the 3C.3a reassortment of HA, M and NS into a 3C.2a1 
background, the 3C.2a2 reassortment event of HA and PB1 into the 3C.2a1 background was also 
investigated.  The same sorts of growth curves and TCID50 assays as used in this thesis were 
conducted to study these viruses, and the findings mirror those reported here.  In MDCK-Siat 
cells, the 2017-18 and 2016-17 3C.2a2 viruses grew to higher titers at earlier timepoints than the 
3C.2a1 viruses isolated in the 2016-17 season (figure 4.3, manuscript in progress).  Reassortant 
3C.2a2 viruses isolated from the 2017-18 outbreak also showed a small but consistent replication 
advantage over 3C.2a2 parental viruses from the 2016-17 season.  Similar results were noted in 
his hNEC growth curves (figure 4.4, manuscript in progress).  This suggested that the 3C.2a2 
reassortment, like its 3C.3a counterpart, had conferred upon the reassortant 3C.2a2 viruses greater 
fitness than was present in the 2016-17 3C.2a1 parental viruses, despite sharing six gene 
segments with them.   
 Both reassortant 3C.3a and 3C.2a2 viruses evinced enhanced viral fitness compared to a 
previously dominant circulating clade, 3C.2a1. These reassortments, taken together, offer a 
compelling case for why the 2017-18 flu season was substantially more severe (8) than the 2016-
17 outbreak.  These reassortment events permitted reassortant viruses to replicate more rapidly to 
higher titers in hNECs than their parental 3C.2a1 viruses.  Since 3C.2a2 viruses especially made 
up the majority of H3N2 cases of influenza during the 2017-18 outbreak, the dominant clade of 
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that season, this increased replication fitness could explain why more people became infected 
with and suffered more severe symptoms from influenza than during the 2016-17 season. 
 
Vaccine Effectiveness in the 2016-17 and 2017-18 US Flu Seasons 
 Vaccination against H3N2 in both the 2016-17 and 2017-18 seasons in the United States 
was achieved using a virus derived from the H3N2 3C.2a Hong Kong strain.  Now that findings 
have been presented demonstrating that the reassortment of 3C.3a HA, M and NS gene segments 
into an otherwise 3C.2a1 background likely increases the replication rate of the reassortant virus, 
it is important to examine how these changes might have impacted the protective effects of the 
H3N2 vaccine deployed in the 2017-18 U.S. flu season. 
 First, it will be helpful to examine both the 2016-17 and 2017-18 flu seasons’ vaccine 
effectiveness.  The vaccine deployed in 2016-17 had an overall vaccine effectiveness against all 
influenza A and B strains of 40%, while specifically against IAV H3N2 it was only 33% effective 
(2).   The overall effectiveness of the 2017-18 vaccine against influenza A and B strains was a 
comparable 38%, but against IAV H3N2 the effectiveness was only 22% among all age groups – 
a one-third decrease in effectiveness compared to the previous flu season (2).  Indeed, examining 
the age stratified effectiveness table for the 2017-18 season reveals that, for every group older 
than eight years, the 95% confidence interval of effectiveness included the null value of 0% (2).  
From a statistical perspective, vaccination for these groups was little better than not receiving a 
vaccine in terms of preventing illness from IAV H3N2.  This was not the case for the 2016-17 
vaccine – while people in the 18-49 and 65 and older age groups had 0% effectiveness within 
their 95% confidence intervals, every other age group statistically received a protective benefit 
receiving the vaccine (2).    
 The reassortment events that generated novel 3C.2a2 and 3C.3a viruses in the 2017-18 
US flu season can help explain this decrease in vaccine effectiveness.  Since the H3N2 
component in both seasons’ vaccines was derived from the same 3C.2a Hong Kong virus, the 
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new reassortant viruses might have been able to escape protective antibodies associated with 
vaccination since no new antibodies would be on hand to protect against the novel HA epitopes 
present on the reassortant 3C.2a2 or 3C.3a viruses.  Indeed, as figure 4.6 shows, in 3C.3a viruses 
isolated during the 2017-18 season there were 14 amino acid changes compared to 3C.2a1 viruses 
that had circulated in 2016-17, with 11 of these occurring in the highly antigenic HA head 
domain.  Given the relatively low vaccine effectiveness of 33% in the 2016-17 season, we must 
assume that the dominant 3C.2a1 viruses of that year and the 3C.2a Hong Kong derived vaccine 
virus likely had numerous amino acid differences in their HA head regions, which would only be 
increased by the 14 differences between 2017-18 reassortant 3C.3a and 2016-17 3C.2a1 viruses.  
However, attention must be paid to the fact that when the vaccines were being evaluated for 
protective benefits by the CDC, they found the 3C.2a1 and 3C.2a2 viruses circulating to be 
antigenically similar to the vaccine selected (2).   One possible phenomenon to explain this 
discrepancy is that the viruses circulating in the 2017-18 outbreak were still antigenically 
recognized by antibodies produced by the immune system, but their replication kinetics allowed 
them to infect a new host, replicate to contagious titers and be transmitted to the next host before 
the antibodies could effectively control the infection.  Further study would be needed to 
determine if this was indeed the case.   
One hypothesis that this research did not explore is that the 3C.2a Hong Kong vaccine 
was partially protective during the 2016-17 outbreak, producing non-sterilizing immunity in 
recipients via cross-reactive antibodies capable of slowing, but not stopping, viral replication.  
However, this cross-reactivity might have been lost due to amino acid residue changes in the 
3C.3a (and, presumably, the 3C.2a2) HA head domain resulting from reassortment before the 
2017-18 season.  If true, this lack of cross-reactive protection could help explain the increase in 





3C.3a Cases on the Ascendance 
 This lack of protection might also explain another interesting phenomenon – the 
proportion of cases of H3N2 influenza resulting from 3C.3a viruses is on the rise.  Thus far the 
2018-19 flu season has been an H1N1 dominant year in the United States, accounting for over 
50% of cases reported by public health laboratories resulting to the CDC, shown in figure 4.7 (5).  
However, 3C.3a now makes up 65% of all H3N2-caused cases of influenza in the United States, a 
65-fold increase in the percentage of cases from the 2017-18 outbreak (or, looking at the raw 
numbers of cases, up from 11 3C.3a cases reported by public health labs to the CDC in 2017-18 
to 383 in 2018-19, a nearly 35-fold increase).   
 This is not surprising: for the two consecutive flu seasons prior to 2018-19, the WHO had 
recommended the same H3N2 component, a 3C.2a virus, be used for the vaccine.  Therefore, 
3C.2a viruses would likely have been under extreme selective pressure to adapt to the robust 
immune response generated in vaccinated individuals.  3C.3a viruses would likely have faced less 
selective pressure, thereby alleviating them of the need to escape protective antibodies generated 
by previous years’ vaccines.  Furthermore, prior to the 2018-19 US flu season, the WHO 
recommended that a new H3N2 component be included in the flu vaccine, derived from a 3C.2a1 
Singapore strain isolated in 2016 (33).  This could explain why the proportion of 3C.2a1 and 
3C.2a2 derived influenza cases in the US were lower than 3C.3a cases (figure 4.7).  3C.3a viruses 
likely would not have encountered robust antibody mediated immunity during the 2018-19 
outbreak.  Indeed, in all three outbreaks, there was no 3C.3a component of the influenza vaccine 
available in the U.S., which might explain the surge in cases resulting from 3C.3a viruses during 
the 2018-19 season (5). 
This substantial increase in the proportion of U.S. influenza cases resulting from 3C.3a 
viruses did not escape the attention of the World Health Organization.  Normally, they release 
their influenza vaccine recommendations in February to provide manufacturers sufficient time to 
prepare stocks.  However, in evaluating the progress of the 2018-19 flu season within the United 
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States, the WHO elected to wait until March 21, 2019 to issue its recommendation, in which they 
advised that the H3N2 component of the vaccine be derived from a 3C.3a virus (24).  This likely 
resulted from their concern about the potential for 3C.3a to become the dominant circulating 
clade in the 2019-2020 influenza season, at least in the United States.  It will be interesting to see 
what effect this change in vaccine strain has, if any, on the proportion of influenza cases resulting 
from H3N2 3C.3a viruses in future outbreaks. 
 
Future Directions 
Most of the work in this thesis centered on the effects of mutations accrued in 3C.3a 
viruses because of the reassortment event.  However, as figure 4.5 shows, there were some 
differences between 2017-18 3C.3a and 2016-17 3C.2a1 viruses that resulted from genetic drift.  
NA in particular showed the greatest number of such drift mutations.  It would be interesting to 
generate a cloned, reassorted virus with 2017-18 3C.3a NA inserted in the 2016-17 3C.2a1 
background and then perform growth curves and TCID50s to characterize any phenotypic 
differences resulting from the NA drift mutations.  Similar work could be done on the PB1 and 
PB2 segments, though each of these had fewer amino acid differences between the 3C.3a and 
3C.2a1 isolates than NA.   
The experiments conducted for this thesis were only able to determine phenotypic 
differences in replication in hNECs and immortalized MDCK-Siat and MDCK cells.  In hNECs, 
which undergo a human innate immune response to infection, it would be interesting to 
characterize what effects various intra- and extracellular defenses were having against the 2017-
18 3C.3a and 2016-17 3C.2a1 viruses.  Any differential protection could explain why 3C.3a 
viruses were capable of replicating more rapidly to higher titers than 2016-17 3C.2a1 viruses.  
Cytokines, chemokines, and other immune molecules could be detected via ELISA and, if present 
on the surface of cells, flow cytometry.  Any differences between cells infected with the different 
viruses could be captured and studied further. 
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As the 2018-19 US flu season winds down, JHU CEIRS has likely stockpiled new 
clinically isolated viruses for analysis.  Since 3C.3a viruses were the dominant H3N2 circulating 
this past season clinical isolates from Baltimore would likely reflect this trend.  One potential 
continuation of this work would begin with sequencing the newly isolated 3C.3a viruses and 
comparing them to the 2017-18 isolates.  Given that this influenza season was mild compared to 
the 2017-18 season, with fewer cases reported to outpatient facilities at its peak (5), there was 
likely not another reassortment event that contributed substantially to an increase in 3C.3a viral 
fitness.  Therefore, it seems likely that any mutations would have arisen through genetic drift 
between this year’s 3C.3a viruses and last year’s.  Sequence comparisons could test these ideas. 
 Building upon the genetic analysis, future experiments to assess the fitness of 2018-19 
3C.3a viruses, especially compared to 3C.3a viruses from previous flu seasons and 3C.2a viruses 
from the 2018-19 season, would be interesting.  Comparing the phenotypes of 3C.2a2 and 3C.3a 
viruses isolated in the 2018-19 season with their 2017-18 counterparts would be interesting for 
several reasons.  First, since 3C.2a2 viruses were far more common in the more severe 2017-18 
outbreak than 3C.3a viruses (Figure 4.1), it might be worth examining 2018-19 3C.2a2 viruses to 
see if they exhibited similar phenotypes to those circulating in 2017-18.  If the 3C.2a2 
reassortment event was one of the key drivers of the severity of the 2017-18 season, then the 
milder 2018-19 season might be the result of mutations attenuating the 3C.2a2 phenotype, which 
could allow 3C.3a viruses to become dominant if their phenotype remained comparable between 
the 2018-19 and 2017-18 seasons.  This hypothesis could be tested with hNEC growth curves and 
subsequent TCID50s to compare replication phenotypes between viral clades isolated in each flu 
season.  Another, similar, hypothesis is that 3C.3a viruses saw an increase in viral fitness 
compared to 3C.2a2 viruses and, therefore, were able to outcompete them.  The same experiments 
discussed above could be used to test this hypothesis.   
However, the relative surge of 3C.3a cases might not be due to a true fitness advantage 
over 3C.2a2 viruses – it might just be that the vaccine available today better protects against 
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3C.2a2 viruses, and therefore there simply are not as many cases of influenza presenting to JHU 
CEIRS resulting from infection with 3C.2a2 viruses.  To test that hypothesis, the affinity of 
antibodies in human serum from the 2018-19 season against both circulating 3C.2a2 and 3C.3a 
viruses could be examined via antibody neutralizing titration assays, which would identify the 
concentrations of serum needed to neutralize the activity of the 3C.3a and 3C.2a2 viruses.  These 
experiments might show that antibodies present in the population during the 2018-19 outbreak 
exhibit greater affinity for 3C.2a2 viruses since there are fewer cases of influenza resulting from 
3C.2a2 infection this outbreak season (figure 4.7), especially given that the H3N2 component of 
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Panel A shows the cases reported to CDC caused by each subtype of influenza A and B in the 
2017-18 season.  IAV H3N2 accounted for most of the cases, and panel B breaks down the 
cases of H3N2 due to clades 3C.2a (including 2a2), 3C.2a1 and 3C.3a. (9) 
Figure 4.2 
This pie chart shows IAV subtype and clade of samples submitted to JH CEIRS from 


















These data show three independent biological replicates, collapsed across clades, of MDCK-
Siat growth curves conducted with 3C.2a1 (green) and 3C.2a2 (orange) parental viruses from 
the 2016-17 U.S. influenza outbreak, and 3C.2a2 reassortant viruses from the 2017-18 season 
(brown).  The 3C.2a2 reassortant viruses grew at earlier timepoints to higher viral titers than 


















These data show three independent biological replicates of hNEC growth curves, collapsed 
across clades,  conducted with 3C.2a1 (green) and 3C.2a2 (orange) parental viruses from the 
2016-17 U.S. influenza outbreak, and 3C.2a2 reassortant viruses from the 2017-18 season 
(brown).  The 3C.2a2 reassortant viruses grew at earlier timepoints to higher viral titers than 
either parental strain.   












This table summarizes sequencing analysis conducted on the gene segments of two viruses 
from each clade studied in this thesis (2016-17 3C.2a1 and 3C.3a parental, and 2017-18 3C.3a 
reassortant).  Each gene segment was compared to a consensus sequence from the 3C.3a 
reassortant viruses, and the number of amino acid differences between each parental clade 
and the reassortant clade are reported here, as well as the % differences. 
Figure 4.6 
Panel A shows the cases reported to CDC caused by each subtype of influenza A and B in the 
2018-19 season.  IAV H1N1 accounted for most of the cases, though H3N2 was still reported 
in approximately 40% of cases. Panel B breaks down the cases of H3N2 due to clades 3C.2a 
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